📊 GYRE Key Takeaways
Is Gyre Therapeutics, Inc.. (GYRE) a Good Investment?
Gyre Therapeutics demonstrates exceptional revenue growth (+6,574% YoY) and maintained profitability (8.5% net margin) with a fortress balance sheet (zero debt, 5.6x current ratio). However, severe cash flow weakness—negative free cash flow of $180K despite $9.9M net income, combined with 60% EPS dilution despite profit growth—signals quality-of-earnings concerns and unsustainable capital deployment that warrants cautious monitoring before capital commitment.
GYRE shows a dramatic shift to profitability on surging revenue and a robust 64.9% gross margin, supported by a debt-free, highly liquid balance sheet. However, weak cash conversion (slightly negative FCF) and a sharp EPS decline suggest dilution and potential revenue quality concerns. Maintain neutral until the company demonstrates consistent, cash-generative growth with sustainable margins.
Why Buy Gyre Therapeutics, Inc.. Stock? GYRE Key Strengths
- Extraordinary revenue growth trajectory (+6,574% YoY) indicating successful commercialization
- Profitable operations with strong 64.9% gross margin and 8.5% net margin demonstrating pricing power
- Zero long-term debt and fortress balance sheet with 5.6x current ratio and $37.1M cash—excellent financial stability
- Debt-free with strong liquidity (5.6x current ratio, $37M cash)
- High gross margin and positive operating/net income
- Significant revenue growth with improving ROE/ROA
GYRE Stock Risks: Gyre Therapeutics, Inc.. Investment Risks
- Critical cash flow disconnect: $9.9M net income but only $1.0M operating cash flow and -$180K free cash flow indicates working capital distress or earnings quality issues
- Severe EPS dilution (-60% YoY) despite net income growth of 96.5% signals substantial equity issuance and shareholder value destruction
- Modest capital returns (ROE 9.3%, ROA 5.9%) despite hypergrowth suggest capital is not being deployed efficiently; sustainability of 6,500%+ growth rate highly questionable
- Weak cash generation despite profits (negative FCF, low OCF)
- Dilution risk signaled by 60% YoY EPS decline
- Potential one-time or non-recurring revenue driving growth and margins
Key Metrics to Watch
- Operating cash flow trend—must improve meaningfully to validate earnings quality
- EPS trajectory—dilution rate must decelerate as growth normalizes
- Days sales outstanding and inventory turnover—assess working capital efficiency
- Operating cash flow margin (cash conversion)
- Gross margin trend
Gyre Therapeutics, Inc.. (GYRE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.60x current ratio provides a solid financial cushion.
GYRE Profit Margin, ROE & Profitability Analysis
GYRE vs Healthcare Sector: How Gyre Therapeutics, Inc.. Compares
How Gyre Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gyre Therapeutics, Inc.. Stock Overvalued? GYRE Valuation Analysis 2026
Based on fundamental analysis, Gyre Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gyre Therapeutics, Inc.. Balance Sheet: GYRE Debt, Cash & Liquidity
GYRE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Gyre Therapeutics, Inc..'s revenue has grown significantly by 457% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.05 reflects profitable operations.
GYRE Revenue Growth, EPS Growth & YoY Performance
GYRE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.5M | $1.6M | $0.01 |
| Q2 2025 | $25.2M | $1.6M | $0.00 |
| Q1 2025 | $22.1M | $3.7M | $0.00 |
| Q3 2024 | $25.5M | $2.9M | $0.01 |
| Q2 2024 | $25.2M | $3.8M | $0.01 |
| Q1 2024 | $24.9M | $4.2M | $0.03 |
| Q1 2022 | $794.0K | -$14.5M | N/A |
| Q3 2021 | $893.0K | -$4.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Gyre Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
GYRE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gyre Therapeutics, Inc.. (CIK: 0001124105)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GYRE
What is the AI rating for GYRE?
Gyre Therapeutics, Inc.. (GYRE) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 63% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GYRE's key strengths?
Claude: Extraordinary revenue growth trajectory (+6,574% YoY) indicating successful commercialization. Profitable operations with strong 64.9% gross margin and 8.5% net margin demonstrating pricing power. ChatGPT: Debt-free with strong liquidity (5.6x current ratio, $37M cash). High gross margin and positive operating/net income.
What are the risks of investing in GYRE?
Claude: Critical cash flow disconnect: $9.9M net income but only $1.0M operating cash flow and -$180K free cash flow indicates working capital distress or earnings quality issues. Severe EPS dilution (-60% YoY) despite net income growth of 96.5% signals substantial equity issuance and shareholder value destruction. ChatGPT: Weak cash generation despite profits (negative FCF, low OCF). Dilution risk signaled by 60% YoY EPS decline.
What is GYRE's revenue and growth?
Gyre Therapeutics, Inc.. reported revenue of $116.6M.
Does GYRE pay dividends?
Gyre Therapeutics, Inc.. pays dividends, with $12.8M distributed to shareholders in the trailing twelve months.
Where can I find GYRE SEC filings?
Official SEC filings for Gyre Therapeutics, Inc.. (CIK: 0001124105) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GYRE's EPS?
Gyre Therapeutics, Inc.. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GYRE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Gyre Therapeutics, Inc.. has a HOLD rating with 63% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GYRE stock overvalued or undervalued?
Valuation metrics for GYRE: ROE of 9.3% (sector avg: 15%), net margin of 8.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GYRE stock in 2026?
Our dual AI analysis gives Gyre Therapeutics, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GYRE's free cash flow?
Gyre Therapeutics, Inc..'s operating cash flow is $1.0M, with capital expenditures of $1.2M. FCF margin is -0.2%.
How does GYRE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.5% (avg: 12%), ROE 9.3% (avg: 15%), current ratio 5.60 (avg: 2).